HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use ELIPHOS® Tablets safely and effectively. See full prescribing information for ELIPHOS® Tablets.

ELIPHOS® Tablets (calcium acetate): 667 mg

Indications and Usage
ELIPHOS® is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. (1)

DOSAGE AND ADMINISTRATION
Starting dose is 2 tablets with each meal. (2)
Titrate the dose every 2-3 weeks until acceptable serum phosphorus level is reached. Most patients require 3-4 tablets with each meal. (2)

Dosage Forms and Strengths
Tablet: 667 mg calcium acetate tablet. (3)

Contraindications
Hypercalcemia. (4)

Warnings and Precautions
Treat mild hypercalcemia by reducing or interrupting ELIPHOS® and Vitamin D. Severe hypercalcemia may require hemodialysis and discontinuation of ELIPHOS®. (5.1)
Hypercalcemia may aggravate digitalis toxicity. (5.2)

Adverse Reactions
The most common (> 10%) adverse reactions are hypercalcemia, nausea and vomiting. (6.1)
In clinical studies, patients have occasionally experienced nausea during calcium acetate therapy. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Hawthorn Pharmaceuticals at 1-800-793-2145 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Drug Interactions
ELIPHOS® may decrease the bioavailability of tetracyclines or fluoroquinolones. (7)
When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after ELIPHOS® or consider monitoring blood levels of the drug. (7)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 8/2016

FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINdications
5 WARNINGS AND PRECAUTIONS
   5.1 Hypercalcemia
   5.2 Concomitant Use with Medications
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE
ELIPHOS® is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).

2 DOSAGE AND ADMINISTRATION
The recommended initial dose of ELIPHOS® for the adult dialysis patient is 2 tablets with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require 3-4 tablets with each meal.

3 DOSAGE FORMS AND STRENGTHS
Tablet: 667 mg calcium acetate per tablet.

4 CONTRAINDICATIONS
Patients with hypercalcemia.

5 WARNINGS AND PRECAUTIONS
5.1 Hypercalcemia
Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate (ELIPHOS®). Avoid the use of calcium supplements, including calcium-based
nonprescription antacids, concurrently with ELIPHOS®.

An overdose of ELIPHOS® may lead to progressive hypercalcemia, which may require emergency measures. Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly. Should hypercalcemia develop, reduce the ELIPHOS® dosage, or discontinue the treatment, depending on the severity of hypercalcemia.

More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing ELIPHOS® therapy.

Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the ELIPHOS® dose or temporarily discontinuing therapy. Decreasing or discontinuing Vitamin D therapy is recommended as well.

Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification. The long term effect of ELIPHOS® on the progression of vascular or soft tissue calcification has not been determined.

Hypercalcemia (>11 mg/dL) was reported in 16% of patients in a 3-month study of solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment.

Maintain the serum calcium-phosphorus (Ca × P) product below 55 mg²/dL².

5.2 Concomitant Use with Medications

Hypercalcemia may aggravate digitalis toxicity.

6 ADVERSE REACTIONS

Hypercalcemia is discussed elsewhere [see Warnings and Precautions (5.1)]

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In clinical studies, calcium acetate has been generally well tolerated.

Calcium acetate was studied in a 3-month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and an alternate liquid formulation of calcium acetate was studied in a two week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients. Adverse reactions (>2% on treatment) from these trials are presented in Table 1.

**Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing Hemodialysis**

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>Total adverse reactions reported for calcium acetate n=167 n (%)</th>
<th>3-mo, open-label study of calcium acetate n=98 n (%)</th>
<th>Double blind, placebo-controlled, cross-over study of liquid calcium acetate n=69</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>6 (3.6)</td>
<td>6 (6.1)</td>
<td>Calcium acetate 0 (0.0) Placebo 0 (0.0)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4 (2.4)</td>
<td>4 (4.1)</td>
<td>Calcium acetate 0 (0.0) Placebo 0 (0.0)</td>
</tr>
<tr>
<td>Hypercalcemia</td>
<td>21 (12.6)</td>
<td>16 (16.3)</td>
<td>Calcium acetate 5 (7.2) Placebo 0 (0.0)</td>
</tr>
</tbody>
</table>
Mild hypercalcemia may be asymptomatic or manifest itself as constipation, anorexia, nausea, and vomiting. More severe hypercalcemia is associated with confusion, delirium, stupor, and coma. Decreasing dialysate calcium concentration could reduce the incidence and severity of ELIPHOS®-induced hypercalcemia. Isolated cases of pruritus have been reported, which may represent allergic reactions.

6.2 Postmarketing Experience
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure.

The following additional adverse reactions have been identified during post-approval of calcium acetate: dizziness, edema, and weakness.

7 DRUG INTERACTIONS
The drug interaction of ELIPHOS® is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl, and hydroxyl groups). ELIPHOS® may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism.

There are no empirical data on avoiding drug interactions between calcium acetate or ELIPHOS® and most concomitant drugs. When administering an oral medication with ELIPHOS® where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after ELIPHOS® or calcium acetate. Monitor blood levels of the concomitant drugs that have a narrow therapeutic range. Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate.

7.1 Ciprofloxacin
In a study of 15 healthy subjects, a co-administered single dose of 4 calcium acetate tablets, approximately 2.7g, decreased the bioavailability of ciprofloxacin by approximately 50%.

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category C
ELIPHOS® contains calcium acetate. Animal reproduction studies have not been conducted with calcium acetate tablets, and there are no adequate and well controlled studies of calcium acetate tablets use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see Warnings and Precautions (5.1)]. Maintenance of normal serum calcium levels is important for maternal and fetal well being. Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. ELIPHOS® treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment.

8.2 Labor and Delivery
The effects of ELIPHOS® on labor and delivery are unknown.

8.3 Nursing Mothers
ELIPHOS® contains calcium acetate and is excreted in human milk. Human milk feeding by a mother receiving ELIPHOS® is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored.
8.4 Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use
Clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to
determine whether they respond differently from younger subjects. Other clinical experience has not
identified differences in responses between elderly and younger patients. In general, dose selection for
an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the
greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other
drug therapy.

10 OVERDOSAGE
Administration of ELIPHOS® in excess of the appropriate daily dosage may result in hypercalcemia
[see Warnings and Precautions (5.1)].

11 DESCRIPTION
ELIPHOS® acts as a phosphate binder. Its chemical name is calcium acetate. Its molecular formula is
$C_4H_6CaO_4$, and its molecular weight is 158.17. Its structural formula is:

![Structural formula of calcium acetate](image)

Each round, white tablet is printed with "CYP 910". Each tablet contains 667 mg calcium acetate, USP
(anhydrous; Ca(CH3COO)$_2$; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, and the following
inactive ingredients: polyethylene glycol 8000, NF; sodium lauryl sulfate, NF; and crospovidone, NF.
ELIPHOS® Tablets (calcium acetate) are administered orally for the control of hyperphosphatemia in
end-stage renal failure.

12 CLINICAL PHARMACOLOGY
Patients with ESRD retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can
precipitate serum calcium resulting in ectopic calcification. Hyperphosphatemia also plays a role in the
development of secondary hyperparathyroidism in patients with ESRD.

12.1 Mechanism of Action
Calcium acetate (ELIPHOS®), when taken with meals, combines with dietary phosphate to form an
insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum
phosphorus concentration.

12.2 Pharmacodynamics
Orally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to
approximately 40% under fasting conditions and up to approximately 30% under non-fasting conditions.
This range represents data from both healthy subjects and renal dialysis patients under various
conditions.
13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment and Fertility

No carcinogenicity, mutagenicity, or fertility studies have been conducted with calcium acetate.

14 CLINICAL STUDIES

Effectiveness of calcium acetate in decreasing serum phosphorus has been demonstrated in two studies of the calcium acetate solid oral dosage form.

Ninety-one patients with end-stage renal disease who were undergoing hemodialysis and were hyperphosphatemic (serum phosphorus >5.5 mg/dL) following a 1-week phosphate binder washout period contributed efficacy data to an open-label, non-randomized study.

The patients received calcium acetate 667 mg tablets at each meal for a period of 12 weeks. The initial starting dose was 2 tablets per meal for 3 meals a day, and the dose was adjusted as necessary to control serum phosphorus levels. The average final dose after 12 weeks of treatment was 3.4 tablets per meal. Although there was a decrease in serum phosphorus, in the absence of a control group the true magnitude of effect is uncertain.

The data presented in Table 2 demonstrate the efficacy of calcium acetate in the treatment of hyperphosphatemia in end-stage renal disease patients. The effects on serum calcium levels are also presented.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Pre-Study</th>
<th>Week 4 *</th>
<th>Week 8</th>
<th>Week 12</th>
<th>p-value †</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phosphorus (mg/dL)†</td>
<td>7.4 ± 0.17</td>
<td>5.9 ± 0.16</td>
<td>5.6 ± 0.17</td>
<td>5.2 ± 0.17</td>
<td>≤0.01</td>
</tr>
<tr>
<td>Calcium (mg/dL)‡</td>
<td>8.9 ± 0.09</td>
<td>9.5 ± 0.10</td>
<td>9.7 ± 0.10</td>
<td>9.7 ± 0.10</td>
<td>≤0.01</td>
</tr>
</tbody>
</table>

* Ninety-one patients completed at least 6 weeks of the study.
† ANOVA of difference in values at pre-study and study completion.
‡ Values expressed as mean ± SE.

There was a 30% decrease in serum phosphorus levels during the 12 week study period (p<0.01). Two-thirds of the decline occurred in the first month of the study. Serum calcium increased 9% during the study mostly in the first month of the study.

Treatment with the phosphate binder was discontinued for patients from the open-label study, and those patients whose serum phosphorus exceeded 5.5 mg/dL were eligible for entry into a double-blind, placebo-controlled, cross-over study. Patients were randomized to receive calcium acetate or placebo, and each continued to receive the same number of tablets as had been individually established during the previous study. Following 2 weeks of treatment, patients switched to the alternative therapy for an additional 2 weeks.

The phosphate binding effect of calcium acetate is shown in the Table 3.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Pre-Study</th>
<th>Post-Treatment</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phosphorus</td>
<td></td>
<td>Calcium Acetate</td>
<td>Placebo</td>
</tr>
</tbody>
</table>

Table 3: Serum Phosphorous and Calcium Levels at Study Initiation and After Completion of Each Treatment Arm
Overall, 2 weeks of treatment with calcium acetate statistically significantly (p<0.01) decreased serum phosphorus by a mean of 19% and increased serum calcium by a statistically significant (p<0.01) but clinically unimportant mean of 7%.

### HOW SUPPLIED

Product: 68151-5204  
NDC: 68151-5204-0 1 TABLET in a PACKAGE

### 17 PATIENT COUNSELING INFORMATION

Inform patients to take ELIPHOS® with meals, adhere to their prescribed diets, and avoid the use of calcium supplements including nonprescription antacids. Inform the patients about the symptoms of hypercalcemia [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].

Advise patients who are taking an oral medication where reduction in the bioavailability of that medication would have clinically significant effect on its safety or efficacy to take the drug one hour before or three hours after ELIPHOS®.

Manufactured for Hawthorn Pharmaceuticals, Inc.  
Morristown, NJ 07960  
1-800-793-2145  
HI257 08/15

**Calcium Acetate**

---

**ELIPHOS**  
calcium acetate tablet

<table>
<thead>
<tr>
<th>Product Information</th>
<th>HUMAN PRESCRIPTION DRUG</th>
<th>Item Code (Source)</th>
<th>NDC: 68151-5204 (NDC: 63717-910)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Type</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Route of Administration
ORAL

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CALCIUM ACETATE (UNII: Y882YXF34X)</td>
<td>CALCIUM ACETATE</td>
<td>667 mg</td>
</tr>
<tr>
<td>CALCIUM ACETATE (CALCIUM CATION - UNII:2M83C4R6ZB)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Product Characteristics

<table>
<thead>
<tr>
<th>Color</th>
<th>Score</th>
<th>Size</th>
<th>Imprint Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>white</td>
<td>no score</td>
<td>2mm</td>
<td>CYP910</td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:68151-5204-0</td>
<td>1 in 1 PACKAGE; Type 0: Not a Combination Product</td>
<td>02/01/2009</td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA078502</td>
<td>02/01/2009</td>
<td></td>
</tr>
</tbody>
</table>

### Labeler
Carilion Materials Management (079239644)

### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carilion Materials Management</td>
<td></td>
<td>079239644</td>
<td>REPACK(68151-5204)</td>
</tr>
</tbody>
</table>

Revised: 8/2016